Editas Medicine (EDIT) Falls 4.05% on May 10

Editas Medicine Inc (NASDAQ: EDIT) has fallen $0.45 (4.05%) and  sits at $10.66, as of 11:55:31 est on May 10.

1,286,462 shares have exchanged hands.

The Company has fallen 22.14% over the last 5 days and shares lost 39.46% over the last 30 days.

Editas Medicine expects its next earnings on 2022-08-03.

For technical charts, analysis, and more on Editas Medicine visit the company profile.

About Editas Medicine Inc

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

To get more information on Editas Medicine Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Editas Medicine Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: www.equities.com/disclaimer

Cigna Beats Q1 Revenue and Earnings Estimates, Raises Full Year Guidance
PepGen Goes Public in $108 Million IPO
Bausch + Lomb Raises $630 Million in IPO, Missing Expectations
Aeglea BioTherapeutics Raises $45 Million Via Registered Direct Offering
Biogen CEO Michel Vounatsos To Step Down After Commercial Failure of Alzheimer’s Drug
Decentralization Drives Progress
Stocks To Watch in 5G Wireless Growth Wave: Jeff Kagan
Betting Against Elon Musk Has Not Been Profitable

Read more here: Source link